Exhibit 2

Premarket Approval (PMA)

FDA Home | Medical Devices | Databases

CDRH SuperSearch

510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC | Inspections

New Search | Back to Search Results

Note: this medical device record is a supplement. The device description may have changed. Be sure to look at the original PMA to get an up-to-date view of this device.

Trade Name	JUVEDERM ULTRA XC AND JUVEDERM ULTRA PLUS XC
Classification Name	Implant, Dermal, For Aesthetic Use
Generic Name	Juvederm Gel Implants
Applicant	ALLERGAN
PMA Number	P050047
Supplement Number	S005
Date Received	08/18/2008
Decision Date	01/07/2010
Product Code	LMH [Registered Establishments With LMH]
Advisory Committee	General & Plastic Surgery
Clinical Trials	NCT00653861
Supplement Type	Normal 180 Day Track
Supplement Reason	Change Design/Components/Specifications - Component
Expedited Review Granted?	No
Combination Product	Yes
Review Memo	Review Memo

Approval Order Statement

Approval for the addition of 0. 3% lidocaine into juvederm ultra and juvederm ultra plus. The device, as modified, will be marketed under the trade name juvederm ultra xc and juvederm ultra plus xc and is indicated for injection into the mid to deep dermis for correction of moderate to severe facial wrinkles and folds (such as nasolabial folds).

Approval Order

Approval Order

Page Last Updated: 03/23/2015

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.

Premarket Approval (PMA)